Please assess the completion status of the following clinical trial:

Trial Title: A Phase II Study of Paclitaxel and Carboplatin in Patients With an Elevated-Risk Cancer of the Uterus

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients must have a elevated risk, surgical stage II, stage IC, grade 2 or 3 adenocarcinoma of the endometrium.~* Patients must have undergone, a total abdominal hysterectomy, bilateral salpingo-oophorectomy, peritoneal washings, and a pelvic and para-aortic lymphadenectomy.~* Patients must have adequate organ function defined as:~  1. Platelets \>/= 100,000/µ~ 2. Granulocytes (ANC)\>/= 1,500/µl~ 3. Creatinine\</= 1.6 mg/dl~ 4. SGOT (AST) \</= 3x upper limits of normal~ 5. Bilirubin within institutional normal limits~* Patients must have adequate performance status (ECOG performance status 0-2 or Karnofsky Performance Status \>40)~* Patients must be age 19 or greater and have signed informed consent.~Exclusion Criteria:~* Patients with history of other malignancies within 5 years (except non- melanoma skin cancer or carcinoma-in-situ of the cervix) are ineligible.~* Patients with high-risk histologic subtypes of endometrial cancer such as papillary serous or clear cell histology are ineligible.~* Patients with histologic evidence of uterine sarcoma, including leiomyosarcoma, carcinosarcoma, endometrial stromal sarcoma, and adenosarcoma are ineligible.~* Patients who have received past pelvic radiotherapy are ineligible.~* Patients receiving any other investigational agents are ineligible.~* Patients with known hypersensitivity to paclitaxel and/or carboplatin are ineligible.

- Gender: FEMALE
- Minimum Age: 19 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Open Label (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).